Chelsea Therapeutics International 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 5, 2010
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On March 5, 2010, we closed on our previously announced registered direct offering of 6,700,000 units. Each unit consisted of (i) one share of our common stock, par value $0.0001 per share, and (ii) a warrant to purchase 0.35 shares of our common stock. In the aggregate, we issued 6,700,000 shares of common stock and warrants to purchase 2,345,000 shares of our common stock. We sold the units at a per unit price of $2.72 for gross proceeds of approximately $18.2 million. We received net proceeds of approximately $16.8 million after deduction of placement agent fees and offering expenses.
The units were offered and sold pursuant to our registration statement on Form S-3 (Registration Statement No. 333-161236), as declared effective by the Securities and Exchange Commission on August 20, 2009.
A copy of the press release announcing the closing of the offering is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.